Responses
Clinical pharmacy and clinical trials (including case series)
CPC-121 Report After One Year Using of Fingolimod, the First Oral Treatment For Multiple Sclerosis: Analysis of Patients in a Neurology Unit
Compose a Response to This Article
Other responses
No responses have been published for this article.